A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions-Reference-Cited by-同舟云学术

A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions

Published:2010-04 Issue:4 Volume:18 Page:852-860
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Sterman Daniel H,Recio Adri,Haas Andrew R,Vachani Anil,Katz Sharyn I,Gillespie Colin T,Cheng Guanjun,Sun Jing,Moon Edmund,Pereira Luana,Wang Xinzhong,Heitjan Daniel F,Litzky Leslie,June Carl H,Vonderheide Robert H,Carroll Richard G,Albelda Steven M

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference27 articles.

1. Advances in the systemic therapy of malignant pleural mesothelioma;Fennell;Nat Clin Pract Oncol,2008

2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

3. Management of malignant pleural effusions;Ruckdeschel;Semin Oncol,1995

4. Interferon beta adenoviral gene therapy in a patient with ovarian cancer;Sterman;Nat Clin Pract Oncol,2006

5. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses;Sterman;Clin Cancer Res,2007

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary management of mesothelioma;Breathe;2024-06

2. Leveraging the pleural space for anticancer therapies in pleural mesothelioma;The Lancet Respiratory Medicine;2024-06

3. Improvements in Systemic Therapies for Advanced Malignant Mesothelioma;International Journal of Molecular Sciences;2023-06-21

4. Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?;Seminars in Respiratory and Critical Care Medicine;2023-06-12

5. Exploring the Expression of the «Dark Matter» of the Genome in Mesothelioma for Potentially Predictive Biomarkers for Prognosis and Immunotherapy;Cancers;2023-05-29